Denali Therapeutics Inc.

DNLI

US24823R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
15.43 ^USD	+3.14%		-3.56%	-28.10%

Apr. 09	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
Apr. 03	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors

March 29, 2024

On March 1, 2024, Denali Therapeutics Inc. closed the transaction. The company will issue securities pursuant to exemption provided under Regulation D from 11 investors.

Latest news about Denali Therapeutics Inc.

UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	Apr. 09	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	Apr. 03	MT
Denali Therapeutics Files Prospectus for Secondary Offering	Mar. 22	MT
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	Feb. 29	CI
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating	Feb. 28	MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	Feb. 27	MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	Feb. 27	MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	Feb. 26	CI
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	Feb. 20	MT
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	Feb. 16	DJ
Sanofi: failure of a phase 2 trial against ALS	Feb. 16	CF
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	Feb. 16	MT
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	Feb. 07	CI
Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium	Feb. 01	CI
Transcript : Denali Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 10:30 AM	Jan. 09
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	Jan. 08	CI
Citigroup Initiates Denali Therapeutics With Buy Rating, Price Target is $32	Dec. 13	MT
Earnings Flash (DNLI) DENALI THERAPEUTICS Reports Q3 Revenue $1.3M	Nov. 07	MT
Denali Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Transcript : Denali Therapeutics Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 11:30 AM	23-09-12
B. Riley Initiates Denali Therapeutics at Buy With $38 Price Target	23-09-06	MT
Blood test for Parkinson's disease promising in early study	23-08-30	RE
Denali Therapeutics Reports Positive Interim Data From Study of Enzyme Replacement Therapy DNL310	23-08-30	MT

Chart Denali Therapeutics Inc.

Duration

Period

More charts

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Denali Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.43 USD

Average target price

40.27 USD

Spread / Average Target

+160.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DENALI THERAPEUTICS INC.	-28.10%	2.2B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs